LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management

被引:335
作者
Cromwell, William C. [1 ,2 ]
Otvos, James D. [3 ]
Keyes, Michelle J. [4 ,5 ]
Pencina, Michael J. [5 ]
Sullivan, Lisa [6 ]
Vasan, Ramachandran S. [4 ,7 ]
Wilson, Peter W. F. [8 ]
D'Agostino, Ralph B. [4 ,5 ]
机构
[1] Presbyterian Ctr Prevent Cardiol, Div Lipoprot Disorders, Charlotte, NC 28204 USA
[2] Wake Forest Univ, Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27109 USA
[3] LipoSci Inc, Raleigh, NC USA
[4] Boston Univ, Sch Med, Framingham Study, Framingham, MA USA
[5] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[6] Boston Univ, Dept Biostat, Boston, MA 02215 USA
[7] Boston Univ, Dept Prevent Med, Cardiol Sect, Boston, MA 02215 USA
[8] Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA USA
关键词
Cardiovascular disease; LDL cholesterol; LDL particle number; Non-HDL cholesterol; Nuclear magnetic resonance; LOW-DENSITY-LIPOPROTEIN; MAGNETIC-RESONANCE-SPECTROSCOPY; CORONARY-HEART-DISEASE; CHOLESTERYL ESTER TRANSFER; APOLIPOPROTEIN-B; NMR-SPECTROSCOPY; APO-B; PLASMA; SUBCLASSES; THERAPY;
D O I
10.1016/j.jacl.2007.10.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: The cholesterol content of low-density lipoprotein (LDL) particles is variable, causing frequent discrepancies between concentrations of LDL cholesterol (LDL-C) and LDL particle number (LDL-P). In managing patients at risk for cardiovascular disease (CVD) to LDL target levels, it is unclear whether LDL-C provides the optimum measure of residual risk and adequacy of LDL-lowering treatment. OBJECTIVE: To compare the ability of alternative measures of LDL to provide CVD risk discrimination at relatively low levels consistent with current therapeutic targets. METHODS: Concentrations of LDL-C and non-HDL-C were measured chemically and LDL-P and VLDL-P were measured by nuclear magnetic resonance in 3066 middle-aged white participants (53% women) without CVD in the Framingham Offspring cohort. The main outcome measure was incidence of first CVD event. RESULTS: At baseline, the cholesterol content per LDL particle was negatively associated with triglycerides and positively associated with LDL-C. On follow-Lip (median 14.8 years), 265 men and 266 women experienced a CVD event. In multivariable models adjusting for nonlipid CVD risk factors, LDL-P was related more strongly to future CVD in both genders than LDL-C or non-HDL-C. Subjects with a low level of LDL-P (<25th percentile) had a lower CVD event rate (59 events per 1000 person-years) than those with an equivalently low level of LDL-C or non-HDL-C (81 and 74 events per 1000 person-years, respectively). CONCLUSIONS: In a large community-based sample, LDL-P was a more sensitive indicator of low CVD risk than either LDL-C or non-HDL-C, suggesting a potential clinical role for LDL-P as a goal of LDL management. (C) 2007 National Lipid Association. All rights reserved.
引用
收藏
页码:583 / 592
页数:10
相关论文
共 39 条
[1]   Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel [J].
Barter, PJ ;
Ballantyne, CM ;
Carmena, R ;
Cabezas, MC ;
Chapman, MJ ;
Couture, P ;
De Graaf, J ;
Durrington, PN ;
Faergeman, O ;
Frohlich, J ;
Furberg, CD ;
Gagne, C ;
Haffner, SM ;
Humphries, SE ;
Jungner, I ;
Krauss, RM ;
Kwiterovich, P ;
Marcovina, S ;
Packard, CJ ;
Pearson, TA ;
Reddy, KS ;
Rosenson, R ;
Sarrafzadegan, N ;
Sniderman, AD ;
Stalenhoef, AF ;
Stein, E ;
Talmud, PJ ;
Tonkin, AM ;
Walldius, G ;
Williams, KMS .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :247-258
[2]   Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis [J].
Barter, PJ ;
Brewer, HB ;
Chapman, MJ ;
Hennekens, CH ;
Rader, DJ ;
Tall, AR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :160-167
[3]   Metabolic origins and clinical significance of LDL heterogeneity [J].
Berneis, KK ;
Krauss, RM .
JOURNAL OF LIPID RESEARCH, 2002, 43 (09) :1363-1379
[4]   Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women [J].
Blake, GJ ;
Otvos, JD ;
Rifai, N ;
Ridker, PM .
CIRCULATION, 2002, 106 (15) :1930-1937
[5]   Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial [J].
Blake, GJ ;
Albert, MA ;
Rifai, N ;
Ridker, PM .
EUROPEAN HEART JOURNAL, 2003, 24 (20) :1843-1847
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[8]   Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol &lt;100 mg/dl [J].
Cromwell, William C. ;
Otvos, James D. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (12) :1599-1602
[9]   Low-density lipoprotein particle number and risk for cardiovascular disease [J].
Cromwell W.C. ;
Otvos J.D. .
Current Atherosclerosis Reports, 2004, 6 (5) :381-387
[10]   Reducing residual risk for patients on statin therapy: The potential role of combination therapy [J].
Davidson, MH .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (9A) :3K-13K